EC Clinical and Medical Case Reports

As one of histone deacetylase inhibitors, butyrate may be overcome by several approaches with anti-multiple myeloma agents and as an adjuvant. Butyrate may mediate its anti-cancer effects as a potential therapeutic prodrug for multiple-myeloma cells apoptosis, partly through microRNA (miRNA) or in collaboration with miRNA. Butyrate fermented in aloe vera gel exerts an anti-tumor effect as a histone deacetylase inhibitor and as an immune checkpoint inhibitor. Case report 1, 2 and 3 showed that the long-time ingestion of aloe vera juice possibly mitigated cervical cancer and a small cerebral neoplasm as an adjuvant.

Keywords: Butyric Acid; Aloe Vera; Histone Deacetylase Inhibitor; Cervical Cancer; Cerebral Neoplasm

1. Watson J and Glasg MB. “Butyric acid in the treatment of cancer”. The Lancet5719 (1933): 746-748.
2. Davie JR. “Inhibition of histone deacetylase activity by butyrate”. Journal of Nutrition7 (2003): 52485-52493.
3. Mandal M., et al. “Butyric acid induces apoptosis by up-regulating Bax expression via stimulation of the c-Jun N-terminal kinase/activation protein-1 pathway in human colon cancer cells”. Gastroenterology 120 (2001): 1-78.
4. Entin-Meer M., et al. “Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radio-sensitizing capacity in the treatment of malignant gliomas”. Molecular Cancer Therapeutics12 (2005): 1952-1961.
5. Mahyar-Roemer M and Roemer K. “p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemo-preventive and therapeutic agents”. Oncogene 20 (2001): 3387-3398.
6. Zhang J., et al. “Sodium butyrate induces endoplasmic reticulum stress and autophagy in colorectal cells: Implications for apoptosis”. PLOS One1 (2016): e14718.
7. Nakagawa H., et al. “Sodium butyrate induces senescence and inhibits the invasiveness of glioblastoma cells”. Oncology Letters2 (2018): 1495-1502.
8. Yagi A and Yu BP. “Putative anti-cancer action of aloe vera via butyrate fermentation”. Journal GHR5 (2017): 2419-2424.
9. He Y., et al. “Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+T cell immunity”. Cell Metabolism 33 (2021): 988-1000.
10. Lu Y., et al. “Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies”. Journal of Hematology and Oncology 15 (2022): 47.
11. Hou H., et al. “Gut microbiota-derived-short-chain fatty acids and colorectal cancer: Ready for clinical translation?” Cancer Letters 526 (2022): 225-235.
12. Panebianco C., et al. “Butyrte, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models”. Biomedical and Pharmacotherapy 151 (2022): 113163.
13. Nakagawa H., et al. “Clinical results of continuous intrathecal or intracavitary administration of sodium butyrate for patients with recurrent and progressive malignant glioma: Experience with 23 cases”. Journal of Clinical Oncology18 (2007): 2040.
14. Chuanbing Z., et al. “Gene modulating butyrate metabolism for assessing clinical prognosis and responses to systematic therapies in hepatocellular carcinoma”. Biomolecules 13 (2023): 52.
15. Shashni B and Nagsaki Y. “Short-chain fatty acid-releasing nano-prodrugs for attenuating growth and metastasis of melanoma”. Acta Biomaterialia (2023).
16. Winstead E. “Can mRNA vaccines help treat cancer? (NIH) (2022).
17. Ali SA., et al. “Functional high-throughput screen identifies microRNAs that promote butyrate-induced death in colorectal cancer cells”. Molecular Therapy: Nucleic Acid (2022).
18. Nomura M., et al. “Association of short chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors”. JAMA Network Open4 (2020): e202895.
19. Kazmierrczak-Siedlecka K., et al. “Sodium butyrate in both prevention and supportive treatment of colorectal cancer”. Frontiers in Cellular and Infection Microbiology 12 (2022): 1023806.
20. Akira Yagi., et al. “Beneficial roles of histone deacetylase inhibitor butyrate to multiple myeloma, acute leukemia and acute myeloid leukemia: Case reports”. Journal of Gastroenterology and Hepatology Research2 (2020): 3107-3112.